Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNZOJ3)

Drug Name
ALXN1820 Drug Info
Indication
Disease Entry ICD 11 Status REF
Sickle-cell disorder 3A51 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMNZOJ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Complement factor P (CFP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CLG561 DMU6R3O Geographic retinal atrophy 9B78.9 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement factor P (CFP) TTLA0VS PROP_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05565092) A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alexion
3 Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342.